A primary goal of the clinical trials efforts of UPCI is to design, implement and analyze innovative, investigator-initiated pilot and phase 1 clinical trials. The development, initiation, implementation and completion of UPCI investigational studies receive substantial and essential support from UPCI Clinical Research Services (CRS). In 2008, 349 of the 1158 total UPCI patients (30%) participating in interventional clinical trials were entered onto institutional studies initiated by UPCI investigators. These investigatorinitiated trials focus on translational research and involve investigators from all of the translational and disease-specific programs of UPCI. Protocol-Specific Research Support has been instrumental in enabling several of these trials. Review of trials supported in the last grant cycle shows that the many PSRS supported trials advanced to the point of support by other mechanisms and/or publication of results. Requests for PSRS support of novel pilot or innovative phase I clinical trials are made by the PI at the time of submission of the trial to the Protocol Review Committee (PRC). Trials are evaluated for innovation and novelty, as well as availability of other sources of support, at the time of PRC submission. Trials with potential to be supported by PSRS funds are forwarded to the Associate Director of Clinical Investigation who makes recommendations to the Director of UPCI for final approval. Funds are used to support the effort of expert research nurses, termed Clinical Research coordinators, who can assist investigators with all aspects of trial implementation and execution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-24
Application #
8382697
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$148,516
Indirect Cost
$78,573
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Qin, Ye; Vasilatos, Shauna N; Chen, Lin et al. (2018) Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene :
Steinman, Justin; Epperly, Michael; Hou, Wen et al. (2018) Improved Total-Body Irradiation Survival by Delivery of Two Radiation Mitigators that Target Distinct Cell Death Pathways. Radiat Res 189:68-83
Yockey, Laura J; Jurado, Kellie A; Arora, Nitin et al. (2018) Type I interferons instigate fetal demise after Zika virus infection. Sci Immunol 3:
Chen, Jingci; Nagle, Alison M; Wang, Yu-Fen et al. (2018) Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors. J Biol Chem 293:3700-3709
Diaz-Perez, Julio A; Killeen, Meaghan E; Yang, Yin et al. (2018) Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis. J Invest Dermatol 138:2595-2605
Evdokimova, Viktoria N; Gandhi, Manoj; Nikitski, Alyaksandr V et al. (2018) Nuclear myosin/actin-motored contact between homologous chromosomes is initiated by ATM kinase and homology-directed repair proteins at double-strand DNA breaks to suppress chromosome rearrangements. Oncotarget 9:13612-13622
Bissel, Stephanie J; Gurnsey, Kate; Jedema, Hank P et al. (2018) Aged Chinese-origin rhesus macaques infected with SIV develop marked viremia in absence of clinical disease, inflammation or cognitive impairment. Retrovirology 15:17
Knickelbein, Kyle; Tong, Jingshan; Chen, Dongshi et al. (2018) Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene 37:4599-4610
Redner, Robert L; Beumer, Jan H; Kropf, Patricia et al. (2018) A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma 59:2595-2601
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10

Showing the most recent 10 out of 1187 publications